Cargando…

Preliminary Investigation of the Safety of Escalating Cannabinoid Doses in Healthy Dogs

Objective: To determine the safety and tolerability of escalating doses of three cannabis oil formulations, containing predominantly CBD, THC, or CBD and THC (1.5:1) vs. placebo in dogs. Design: Randomized, placebo-controlled, blinded, parallel study. Animals: Twenty healthy Beagle dogs (10 males, 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaughn, Dana, Kulpa, Justyna, Paulionis, Lina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029731/
https://www.ncbi.nlm.nih.gov/pubmed/32118071
http://dx.doi.org/10.3389/fvets.2020.00051
_version_ 1783499227928723456
author Vaughn, Dana
Kulpa, Justyna
Paulionis, Lina
author_facet Vaughn, Dana
Kulpa, Justyna
Paulionis, Lina
author_sort Vaughn, Dana
collection PubMed
description Objective: To determine the safety and tolerability of escalating doses of three cannabis oil formulations, containing predominantly CBD, THC, or CBD and THC (1.5:1) vs. placebo in dogs. Design: Randomized, placebo-controlled, blinded, parallel study. Animals: Twenty healthy Beagle dogs (10 males, 10 females). Methods: Dogs were randomly assigned to one of five treatment groups (n = 4 dogs per group balanced by sex): CBD-predominant oil, THC-predominant oil, CBD/THC-predominant oil (1.5:1), sunflower oil placebo, medium-chain triglyceride oil placebo. Up to 10 escalating doses of the oils were planned for administration via oral gavage, with at least 3 days separating doses. Clinical observations, physical examinations, complete blood counts, clinical chemistry, and plasma cannabinoids were used to assess safety, tolerability, and the occurrence of adverse events (AEs). AEs were rated as mild, moderate, or severe/medically significant. Results: Dose escalation of the CBD-predominant oil formulation was shown to be as safe as placebo and safer than dose escalation of oils containing THC (CBD/THC oil or THC oil). The placebo oils were delivered up to 10 escalating volumes, the CBD oil up to the tenth dose (640.5 mg; ~62 mg/kg), the THC oil up to the tenth dose (597.6 mg; ~49 mg/kg), and the CBD/THC oil up to the fifth dose (140.8/96.6 mg CBD/THC; ~12 mg/kg CBD + 8 mg/kg THC). AEs were reported in all dogs across the five groups and the majority (94.9%) were mild. Moderate AEs (4.4% of all AEs) and severe/medically significant AEs (0.8% of all AEs) manifested as constitutional (lethargy, hypothermia) or neurological (ataxia) symptoms and mainly occurred across the two groups receiving oils containing THC (CBD/THC oil or THC oil). Conclusions and clinical significance: Overall, dogs tolerated dose escalation of the CBD oil well, experiencing only mild AEs. The favorable safety profile of 10 escalating doses of a CBD oil containing 18.3–640.5 mg CBD per dose (~2–62 mg/kg) provides comparative evidence that, at our investigated doses, a CBD-predominant oil formulation was safer and more tolerated in dogs than oil formulations containing higher concentrations of THC.
format Online
Article
Text
id pubmed-7029731
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-70297312020-02-28 Preliminary Investigation of the Safety of Escalating Cannabinoid Doses in Healthy Dogs Vaughn, Dana Kulpa, Justyna Paulionis, Lina Front Vet Sci Veterinary Science Objective: To determine the safety and tolerability of escalating doses of three cannabis oil formulations, containing predominantly CBD, THC, or CBD and THC (1.5:1) vs. placebo in dogs. Design: Randomized, placebo-controlled, blinded, parallel study. Animals: Twenty healthy Beagle dogs (10 males, 10 females). Methods: Dogs were randomly assigned to one of five treatment groups (n = 4 dogs per group balanced by sex): CBD-predominant oil, THC-predominant oil, CBD/THC-predominant oil (1.5:1), sunflower oil placebo, medium-chain triglyceride oil placebo. Up to 10 escalating doses of the oils were planned for administration via oral gavage, with at least 3 days separating doses. Clinical observations, physical examinations, complete blood counts, clinical chemistry, and plasma cannabinoids were used to assess safety, tolerability, and the occurrence of adverse events (AEs). AEs were rated as mild, moderate, or severe/medically significant. Results: Dose escalation of the CBD-predominant oil formulation was shown to be as safe as placebo and safer than dose escalation of oils containing THC (CBD/THC oil or THC oil). The placebo oils were delivered up to 10 escalating volumes, the CBD oil up to the tenth dose (640.5 mg; ~62 mg/kg), the THC oil up to the tenth dose (597.6 mg; ~49 mg/kg), and the CBD/THC oil up to the fifth dose (140.8/96.6 mg CBD/THC; ~12 mg/kg CBD + 8 mg/kg THC). AEs were reported in all dogs across the five groups and the majority (94.9%) were mild. Moderate AEs (4.4% of all AEs) and severe/medically significant AEs (0.8% of all AEs) manifested as constitutional (lethargy, hypothermia) or neurological (ataxia) symptoms and mainly occurred across the two groups receiving oils containing THC (CBD/THC oil or THC oil). Conclusions and clinical significance: Overall, dogs tolerated dose escalation of the CBD oil well, experiencing only mild AEs. The favorable safety profile of 10 escalating doses of a CBD oil containing 18.3–640.5 mg CBD per dose (~2–62 mg/kg) provides comparative evidence that, at our investigated doses, a CBD-predominant oil formulation was safer and more tolerated in dogs than oil formulations containing higher concentrations of THC. Frontiers Media S.A. 2020-02-11 /pmc/articles/PMC7029731/ /pubmed/32118071 http://dx.doi.org/10.3389/fvets.2020.00051 Text en Copyright © 2020 Vaughn, Kulpa and Paulionis. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Veterinary Science
Vaughn, Dana
Kulpa, Justyna
Paulionis, Lina
Preliminary Investigation of the Safety of Escalating Cannabinoid Doses in Healthy Dogs
title Preliminary Investigation of the Safety of Escalating Cannabinoid Doses in Healthy Dogs
title_full Preliminary Investigation of the Safety of Escalating Cannabinoid Doses in Healthy Dogs
title_fullStr Preliminary Investigation of the Safety of Escalating Cannabinoid Doses in Healthy Dogs
title_full_unstemmed Preliminary Investigation of the Safety of Escalating Cannabinoid Doses in Healthy Dogs
title_short Preliminary Investigation of the Safety of Escalating Cannabinoid Doses in Healthy Dogs
title_sort preliminary investigation of the safety of escalating cannabinoid doses in healthy dogs
topic Veterinary Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029731/
https://www.ncbi.nlm.nih.gov/pubmed/32118071
http://dx.doi.org/10.3389/fvets.2020.00051
work_keys_str_mv AT vaughndana preliminaryinvestigationofthesafetyofescalatingcannabinoiddosesinhealthydogs
AT kulpajustyna preliminaryinvestigationofthesafetyofescalatingcannabinoiddosesinhealthydogs
AT paulionislina preliminaryinvestigationofthesafetyofescalatingcannabinoiddosesinhealthydogs